Human norovirus is a leading cause of acute gastroenteritis worldwide in a plethora of residential and commercial settings, including restaurants, schools, and hospitals. Methods for easily detecting the virus and for treating and preventing infection are critical to stopping norovirus outbreaks, and inactivation via nanoparticles (NPs) is a more universal and attractive alternative to other physical and chemical approaches. Using norovirus GI.1 (Norwalk) virus-like particles (VLPs) as a model viral system, this study characterized the antiviral activity of Au/CuS core/shell nanoparticles (NPs) against GI.1 VLPs for the rapid inactivation of HuNoV. Inactivation of VLPs (GI.1) by Au/CuS NPs evaluated using an absorbance-based ELISA indicated that treatment with 0.083 μM NPs for 10 min inactivated ~50% VLPs in a 0.37 μg/ml VLP solution and 0.83 μM NPs for 10 min completely inactivated the VLPs. Increasing nanoparticle concentration and/or VLP-NP contact time significantly increased the virucidal efficacy of Au/CuS NPs. Changes to the VLP particle morphology, size, and capsid protein were characterized using dynamic light scattering, transmission electron microscopy, and Western blot analysis. The strategy reported here provides the first reported proof-of-concept Au/CuS NPs-based virucide for rapidly inactivating human norovirus.
Citation: Broglie JJ, Alston B, Yang C, Ma L, Adcock AF, Chen W, et al. (2015) Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles. PLoS ONE 10(10): e0141050. https://doi.org/10.1371/journal.pone.0141050
Editor: Yongchang Cao, Sun Yat-sen University, CHINA
Received: May 19, 2015; Accepted: October 1, 2015; Published: October 16, 2015
Copyright: © 2015 Broglie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This study was supported by Agriculture and Food Research Initiative Competitive Grant no. 329 2011-68003-30395 from the USDA National Institute of Food and Agriculture (NIFA).
Competing interests: The authors have declared that no competing interests exist.
Human norovirus (HuNoV) is a leading food and waterborne pathogen that causes nonbacterial, acute gastroenteritis outbreaks worldwide [1–3], accounting for more than 21 million illnesses, and contributing to about 70,000 hospitalizations and at least 570 deaths in the United States each year (Centers for Disease Control and Prevention, 2013). Noroviruses are single-stranded RNA, non-enveloped viruses in the Calicivirdae family. They are classified into five genogroups (GI to GV) and further subclassified into genotypes and genetic clusters based on their capsid sequence . Their genetic diversity, low (18 particles or less) infectious dose , myriad of foodborne and waterborne transmission routes, and prolonged (few hours to several weeks) survival on multiple environmental surfaces [5, 6] lead to frequent epidemics in a variety of residential and commercial settings, including restaurants, schools, nursing homes, and cruise ships [7–12]. In addition, the lack of general population immunity [3, 13]–symptomatic, asymptomatic, and healthy individuals are all capable of spreading HuNoV –greatly increases the likelihood of widespread infection, especially among young children, the elderly, and immunocompromised persons [15, 16].
To effectively prevent norovirus outbreaks, scientists have been working to develop methods for easily detecting the virus and for treating and preventing norovirus infection. However, two of the major challenges in norovirus research are the inability to grow the virus in a cell culture system and the lack of a good animal model system for studying details of how viruses cause illness and testing antiviral agents. In recent years, various viral inactivation strategies have been proposed and studied using norovirus virus-like particles (VLPs)  or norovirus surrogates such as murine norovirus, feline calicivirus, and poliovirus [18, 19].
Norovirus VLPs are replication-incompetent, macromolecular protein assemblies with capsid structures and antigenic properties resembling those of native noroviruses [20–22]. Each VLP is ~38 nm in diameter and has repeating arch-like surface features. These arches are formed by 90 dimers of a single capsid protein and contain both a shell and protruding (P) domain. The former houses the capsid’s N-terminus, consisting of 225 residues of the 530 amino acid (aa) sequence , while the latter forms the topmost P2 domain of the arch-like structure and the P1 domain which connects the shell and P2 domain. The P1 and P2 domains are consisted of the C-terminus and the central regions of the amino acid sequence, respectively . The norovirus VLPs are morphologically and antigenically similar to native virus, and have been widely used in experimental approaches for characterizing these viruses and studying inactivation methods for noroviruses over the past 20 years.
Many of the inactivation strategies strive to prevent intact HuNoV capsids from recognizing their binding sites and entering into host cells to replicate  by damaging genomic RNA or capsid proteins [25, 26]. Reported inactivation methods included chemical disinfection [27–30], chitosan additives [31, 32], high pressure homogenization , pulsed light , UV irradiation , variations in pH [34, 35], high temperature treatment [36–39], high pressure treatment [17, 40–42], and radiation treatment . Many of these studies used surrogate viruses in their studies, meanwhile there are an increased number of studies using VLPs in laboratory research for initiative studies of novel/improved methods for inactivation of novoviruses [17, 18], due to their similarity to native virus and availability to laboratory users.
Research has shown that the most promising virucides are those that directly bind to the viral capsid , making inactivation via nanoparticles (NPs) a more universal and attractive alternative to other physical and chemical strategies. Metallic NPs owe their broad-spectrum antimicrobial activity to their small size and high surface to volume ratio , and many NP types, including silver [45, 46], copper iodide , and titanium dioxide  can inactivate bacterial cells and norovirus surrogates by interacting with the cell membrane, causing leakage of intracellular substances and cell death  or by interacting with (and denaturizing) capsid proteins.
Using norovirus GI.1 (Norwalk) virus-like particles (VLPs) as a model viral system, this study characterized the intrinsic virucidal properties of gold/copper sulfide (Au/CuS) core/shell nanoparticles against GI.1 VLPs for the rapid inactivation of HuNoV. Au/CuS NPs exhibited antimicrobial activity against Bacillus anthracis cells , but their efficacy as an antiviral has yet to be evaluated. Au/CuS NPs offer many advantages to other metallic NPs, namely lower cost and ready availability compared to silver , and to other conventional methods via continuous release of copper ions into solution without reducing agents . In this study, inactivation of VLPs (GI.1) by Au/CuS NPs was evaluated using an absorbance-based ELISA. Both nanoparticle concentration and VLP-NP contact time were investigated as possible variables that affect the virucidal efficacy of Au/CuS NPs. Changes to the VLP particle morphology, size, and capsid protein were characterized using dynamic light scattering, transmission electron microscopy, and Western blot analysis. The strategy reported here provides the first reported proof-of-concept Au/CuS NPs-based inactivation approach for inactivating human norovirus.
Materials and Methods
VLPs, Antibodies, and Chemicals
Stock solutions of GI.1 VLPs and monoclonal anti-GI.1 VLP antibody (mAb 3901) at 3.7 and 2.2 mg/mL, respectively, were obtained from Dr. Robert Atmar’s laboratory at the Baylor College of Medicine (Houston, TX). Goat anti-mouse IgG H&L antibody conjugated to horseradish peroxidase (HRP) (0.5 mg/mL) was purchased from Abcam (Cambridge, MA). Goat anti-mouse antibody labeled with IRDye® 800CW infrared dye (0.5 mg) was purchased from LI-COR Biosciences (Lincoln, NE). Phosphate buffered saline (PBS), pH 7.4, was prepared in-house from a 1X (0.01 M) PBS recipe (Cold Spring Harbor Protocols) using NaCl, KCl, Na2HPO4, and KH2PO4, all purchased from Fisher Scientific.
Au/CuS Core/Shell Nanoparticles
Au/CuS core/shell NPs were acquired from Professor Wei Chen’s laboratory at the University of Texas at Arlington. Detailed reaction conditions and procedures have been reported previously , but, briefly, the NPs were synthesized using a two-step method by first growing gold NPs as cores using the seeded growth method and then coating these cores with CuS nanoshell. The core/shell structure was confirmed by high resolution transmission electron microscope (HRTEM) imaging of the Au and CuS lattice planes in the core and the shell, respectively, and by spectrophotometric observation of the characteristic absorption peaks for Au and CuS at 531 and 981 nm, respectively . The synthesized Au/CuS NPs were 2–5 nm in diameter with an initial concentration of 83 μM.
Au/CuS NPs Treatment to GI.1 VLPs
For treatment with NPs, aliquots (17.5 μL) of purified GI.1 VLP suspensions at various concentrations (to reach the final VLP concentrations at 0.37, 3.7, and 5.6 μg/mL) were mixed with 17.5 μL of various Au/CuS NP concentrations ranging from 0.083 to 20.75 μM (to reach the final concentrations ranging from 0.0083 to 2.075 μM) in 1.5 mL microcentrifuge tubes. All solutions were brought to 175.0 μL using 0.01M PBS and continuously agitated at 30–32 RPM using an end-over-end rotator (Dynal Biotech, Inc.; Lake Success, NY) for various treatment times ranging from 10 min to 4 h. Untreated (no NPs) solutions were prepared identically to the VLPs + NPs solutions and used as controls for each treatment time. After treatment, all solutions were centrifuged at 7500 RPM (5283xg) for 5 min using an Eppendorf microcentrifuge (Hamburg, Germany) to separate the NPs and VLPs.
Evaluation of NPs’ Antiviral Activity
The virucidal efficacy of the Au/CuS NPs was evaluated using an ELISA method previously reported by our group . Briefly, 50.0 μL of untreated or treated VLP solution was dispersed into the wells of a medium-binding 96-well polystyrene plate (Costar™ 3591; Corning Incorporated, Corning, NY) and incubated at room temperature for 1 h. 50.0 μL of 0.01M PBS was used as a blank. Each well was washed with 0.01 M PBS and blocked with 100.0 μL of SuperBlock T20 (PBS) Blocking Buffer (Thermo Scientific). The wells were washed with PBS and sequentially treated with 0.2 μg/mL mAb 3901 anti-GI.1 VLP and 0.1 μg/mL HRP-labeled goat anti-mouse IgG antibody solutions for 1 h. The plate was washed twice with 100.0 μL aliquots of 0.01 M PBS + 0.05% Tween™ 20 between steps. Following the final washing step, each well was reacted with 100 μL of TMB (3,3’,5,5’-tetramethylbenzidine) Peroxidase Substrate Microwell Substrate System (KPL, Gaithersburg, MD) for 10 min, filled with 50.0 μL of Stop Solution (KPL, Gaithersburg, MD), and the absorbance of each well was read at 450 nm using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA). Reduced absorbance in NP-treated samples (compared to an untreated control) indicated reduced concentration of intact VLPs due to damage to the capsid surface proteins and associated VLP inactivation.
Evaluation of VLP Capsid Protein Degradation using Western blot
The effect of NP treatment on the VLP capsid proteins was assessed via immunoblotting. Each NP-treated or untreated VLP solution (5.0 μL containing 0, 0.083, 0.83, and 1.66 μM final concentrations of Au/CuS NPs and 3.7 μg/mL GI.1 VLPs) was mixed with 2.5 μL of 4X LDS Non-Reducing Sample Buffer (Thermo Scientific), 1.0 μL of 1M DTT (Fisher Scientific), and 1.5 μL of DI H2O. The denatured samples were resolved onto a precast 1.0mm x 10-well NuPAGE® 4–12% Bis-Tris gel (Life Technologies; Grand Island, NY) using 1X MOPS SDS Running Buffer (Invitrogen; Carlsbad, CA) and transferred to an Odyssey® nitrocellulose membrane (LI-COR Biosciences) using 1X NuPAGE® Transfer Buffer + 10% MeOH. The membrane was blocked with 10.0 mL of 1:1 Blocking Buffer for Fluorescent Western Blotting (Rockland Immunochemicals Inc.; Limerick, PA) + 0.1% PBST. The latter was prepared from HyClone™ Dulbecco’s Phosphate Buffered Saline Solution (Fisher Scientific) and Tween™ 20. The blocked membrane was sequentially probed with 0.2 μg/mL mAb 3901 anti-GI.1 VLP and 0.07 μg/mL goat anti-mouse IRDye® 800CW antibodies, both diluted in 10.0 mL of 1:1 Rockland Blocking Buffer + 0.1% PBST, and the bound antibodies were visualized with a LI-COR Odyssey Infrared Imaging System. All samples were compared against SeeBlue® Plus2 Prestained Standard (Invitrogen).
Characterization of Particle Interactions During Treatment
Capsid size was characterized using DLS to determine how the Au/CuS nanoparticles interacted with the VLPs during treatment. 100.0 μL of each NP-treated and untreated VLP solution was analyzed using a Zetasizer Nano ZSP (Malvern Instruments, Westborough, Massachusetts) and disposable BRAND® microcuvettes (Sigma-Aldrich). Suspensions were measured six times each using 10–15 readings per measurement, and the resulting data were averaged to obtain a mean size distribution profile for each solution. Comparing the averaged intensity of the scattered light allows for efficient comparison of VLP dissociation under different conditions .
Transmission electron microscopic (TEM) imaging
TEM were acquired using a FEI Technai G2 Twin TEM (Hillsboro, OR) at the Shared Materials Instrumentation Facility (SMIF) at Duke University. To prepare VLPs samples for TEM, a drop of NP-treated or untreated VLP solution was placed on formvar/carbon TEM grids (Electron Microscopy Sciences; Hatfield, PA) for 10 min. All grids were wicked (to remove excess fluid) using filter paper and then stained with 2% uranyl acetate prior to imaging.
Results and Discussion
Inactivation Effect of Au/CuS NP Treatment on VLPs
We first examined the effect of NPs treatment on VLPs using the ELISA method in which the binding capacity of VLPs to the monoclonal anti-GI.1 VLP antibody (mAb 3901) was evaluated. Fig 1 shows the absorbance signal reductions after VLPs (at two concentration levels: 0.37 and 3.7 μg/mL) were treated with Au/CuS NPs at final concentrations ranging from 0.0083 μM to 1.66 μM for 10 min. For the 0.37 μg/mL VLPs, compared to the untreated control, the inactivation effect was apparent at the treatment with 0.083 μM Au/CuS NPs. Also, there was a marked increase in antiviral activity between 0.083 μM and 0.415 μM, and the VLPs appeared to be completely inactivated at treatments with 0.83 μM and higher NPs. For the denser VLPs at 3.7 μg/mL, treatment with higher concentration of NPs (at 0.415 μM) exhibited a marked antiviral activity, but there were reportable absorbance values at the treatments across the entire tested Au/CuS NP concentration range. This indicates that only partial inactivation was achieved even at high Au/CuS NPs concentrations (up to 1.66 μM).
Absorbance was measured using the three-hour ELISA, and all solutions contained an equal volume of NPs. Reduced absorbance indicates structural damage to the capsid surface proteins and associated VLP inactivation. In each series, the same letters on the columns indicate no statistically difference, and the different letters indicate statistically different.
It turned out that the treatment time had a strong effect on VLP inactivation. Fig 2 shows the absorbance value reductions in VLPs detection by ELISA upon treatment with 0.083 μM Au/CuS for various time periods ranging form 10 min to 4 h. After only 10 and 30 min of treatment, the average absorbance of the treated VLP solutions changes by 35% and 79%, respectively, when compared to the corresponding control solutions, indicating the inactivation of VLPs by Au/CuS NPs was effective and rapid. Also, no absorbance values can be detected for the longer treatment times, while the untreated solutions have similar absorbance values, regardless of treatment time.
Absorbance was measured using the three-hour ELISA, and new VLP and NP solutions were prepared for each time point. Reduced absorbance suggests structural damage to the capsid surface proteins and is indicative of VLP inactivation.
The results suggested the NP treated VLPs were morphologically and/or antigenically different from the untreated VLP capsids in that the binding capacity to the detection antibody (mAb 3901) was reduced remarkably. The reduced binding capacity could be due to two possible reasons: NPs might bind to the VLP capsids that may serve to block the binding of mAb3901 to VLPs, or the binding of NPs to VLPs may further cause protein degradation thus the loss/damage of epitopes for mAb 3901 binding.
Effect of NP Treatment on VLP Capsid Protein
We then performed Western blotting to examine protein degradation in VLPs upon Au/CuS NP treatment. Fig 3A shows the immunoblot for VLPs treated with different concentrations of Au/CuS NPs, along with controls. Total proteins were separated by SDS-PAGE and subjected to Western blotting using mAb 3901 primary and fluorescent secondary antibodies. It is known that mAb 3901 can bind to either the full-length (58K) capsid protein or a 32K protein fragment in the P domain [24, 53]. It recognizes a continuous epitope on the C-terminal of the capsid protein, as it was able to bind to the 58K capsid protein and the 32K protein product in Western blot even when the proteins were denatured by boiling prior to analysis . The Western blot here shows that all samples presented a band near 32K, but the relative intensities of the bands obviously varied for the samples treated with different concentrations of NPs. Taking the band intensity of the VLP samples without NP treatment as a base value (taken as 1), the normalized band intensities of the samples treated with different concentrations of NPs are shown in Fig 3B. The results clearly showed that the amount of this 32K protein product reduced significantly as the VLPs were treated with NPs. The treatment with the lowest concentration of NPs (0.83 μM) in the test caused ~86% reduction of this protein, and as the NPs concentration increased to 10 to 20 times higher, it reduced even more and reached a maximum 92–95% reduction. The reduced amount of this protein after NPs treatments suggested that Au/CuS NPs treatment most likely cause degradation (break-down) of this 32K P domain protein.
(A) Immunoblotting with normalized signals (relative to lane 4) for lane 1: MW marker; lane 2: untreated VLP solution; lane 3: VLPs treated with 0.083 μM Au/CuS NPs; lane 4: VLPs treated with 0.83 μM Au/CuS NPs; and lane 5: VLPs treated with 1.66 μM Au/CuS NPs. (B) The relative intensities of the band at approximately 32K. (C) the relative intensities of the band of a small fragment of the capsid protein at approximately 22K. All solutions contain an equal volume of 3.7 μg/mL GI.1 VLPs and/or nanoparticles, and all solutions were centrifuged for 5 min. The same letters on the columns indicate no statistical difference, and the different letters indicate a statistical difference.
It is also known that mAb 3901 also recognizes a domain between amino acid 453 and amino acid 495, and the lower band (~22K band) in the Western blot is likely a fragment that contains this sequence. As shown in Fig 3C, this band was less pronounced in the control samples, but was significantly increased in the NPs-treated VLP samples. In fact, normalizing the band intensities relative to the untreated control samples showed that this protein fragment actually increased 2.7- to 3.1-fold in the NPs-treated samples. Again this observation suggested it is likely that the NP treatments caused the 32K P domain protein to break down into smaller fragments. The ~22K product was possibly one of the fragments and contained the domain (aa 453–495) that was recognized by mAb3901. It is not surprising that NPs treatment caused VLP capsid protein degradation, as several other inactivation methods treatments have been reported to cause VLP capsid protein degradation, such as Gamma radiation , high pressure treatment . And especially, capsid protein degradation in human norovirus was observed upon contact with copper alloy surface  which is closely relevant to this study. At this stage, however, it is unclear about the detailed mechanisms on how Au/CuS NPs can cause the capsid protein to break down, and further studies are necessary to elucidate the detailed mechanisms.
NPs Treatment Damages Virus Particles
We further investigated the particle size profiles in VLP suspensions before and post-NPs treatment using dynamic light scattering (DLS). Fig 4 shows the mean particle diameter profiles of VLP suspension, Au/CuS NPs suspension, and the VLP suspension after NP treatment. As expected, for the VLP suspensions, the peak between 10 to 100 nm represented the VLP particles in the suspension, as it is known that the diameter of an assembled norovirus VLP is ~38 nm , but smaller and larger particles with 20 to 90 nm diameter were also observed . For the Au/CuS NP suspensions, the peak between 1 and 10 nm indicated the profile of the NPs diameters, which was very close to the previously reported size of 2–5 nm (as determined by SEM/TEM). For VLPs + Au/CuS NPs suspensions, it is obvious that the VLP peak disappeared after 10 min of mixing, suggesting that the intact VLPs may have broken into smaller fragments. Tests on VLP suspensions treated with NPs at other concentrations (0.83 μM and 1.245 μM) showed similar results where the peak between 10 and 100 nm before treatment shifted to <10 nm after NPs treatments (S1 Fig).
(A) Mean size of small particles (<10 nm) in treated and untreated VLP solutions. VLP solutions at 5.6 μg/mL were dosed with 2.08 μM Au/CuS NPs, and all solutions were rotated end-over-end and centrifuged for 10 and 5 min, respectively. Particle size was measured using dynamic light scattering. (B) TEM images of untreated VLPs, and VLPs treated with 0.083 μM and 0.83 μM for 30 min. Arrows indicate examples of untreated VLPs which are round shaped circles in light color and aggregated together; Treatment with 0.083 μM NPs caused VLPs lost integrity in the aggregate; Treatement with 0.83 μM NPs caused VLPs to break down into fragments and no intact VLP can be seen.
Damage to VLPs upon Au/CuS NP treatment was confirmed using TEM (Fig 4B). As shown in the images, the untreated VLPs were intact and readily identifiable with well-defined, regular round shape. However, these features were less distinct after treatment with 0.083 μM Au/CuS NPs. The treatment with the 0.83 μM NPs appeared to break the VLPs’ capsids into fragments and no intact VLPs were observed. The imaging results confirmed that the VLP capsid underwent physical degradation and eventual rupture as the nanoparticle concentration increased from 0.083 μM to 0.83 μM (Fig 4B). This cumulative loss of capsid structural integrity is consistent with the particle size profile changes observed in the DLS spectra.
Possible Mechanisms of Au/CuS NP Inactivating VLPs
Based on the reported mechanisms of how NPs inactivate bacteria, direct contact and damage to the cell membrane is a common mechanism for many different NPs [56–58]. Other possible routes include suppression of energy metabolism , inhibition of enzyme activity and induced oxidative stress , increased membrane permeability [60–62], and physical piercing . Although these mechanisms might not all be applicable to how Au/CuS NPs inactivate VLPs, it is likely that some of these mechanisms are involved. The above observations suggested that the Au/CuS NPs may inactivate the VLPs by direct contact/binding to the VLPs and further physically damaging the capsid.
Considering the core/shell structure of the Au/CuS nanoparticles, the CuS shell is the component that most likely interacts with the VLP capsid. Little is known about the antimicrobial activity of pure CuS nanoparticles based on published literature. However, another member of the Cu compound family, the CuO NP, has recently been reported to show antimicrobial activity to several types of microorganisms [64–66]. Based on the action of CuO NPs and other metal oxide NPs (such as ZnO), the release of soluble metal ions (such as Cu2+, Zn2+) from the NPs largely influenced their toxicity . Our previous study on Au/CuS NPs inactivation of B. anthracis spores and cells showed that Au/CuS NPs bind to and damage the cell membrane, creating an osmotic imbalance, efflux of cytoplasmic content, and associated cell rupture and death . More relevant studies using copper alloys as antiviral surfaces for murine norovirus—an HuNoV surrogate—showed the virus was destroyed within 60 min , with the largest difference in inactivation rate occurring within the first 30 min of contact . These studies reported that the mechanism of copper inactivation of noroviruses involves both degradation of the RNA and destruction of the capsid. A more recent study also reported that exposure to copper alloys destructed the capsid and genome of GII.4 human norovirus . These reports suggested that the Cu component may be a key factor controlling the antiviral activity of Au/CuS NPs to VLPs. And our observations on VLPs’ capsid protein degradation and the loss of capsid integrity by Au/CuS NPs treatment are consistent with the observations reported by these relevant studies [54, 67–69].
It is also possible that an intact NP can diffuse across the cell membrane or virus capsid, or that Cu2+ solute from the NPs can enter cells through the transport and ion/voltage-gated channels . While NPs themselves can interact with oxidative organelles or redox active proteins to induce reactive oxygen species (ROS) in cells, Cu2+ produced by the NPs can also induce ROS by various chemical reactions, and ROS can break DNA strands and alter gene expression . Another possible mechanism is that Cu2+ can chelate with biomolecules or dislodge the metal ions in some metalloproteins, leading to dysfunctional proteins and further cell inactivation . These mechanisms are likely applicable to how Au/CuS NPs interact with VLPs, leading to capsid protein degradation and breakdown. However, as the study of Au/CuS NPs’ antiviral activity is in a very early stage, its detailed mechanisms are not fully understood. Further studies using different viruses and experimental conditions, systematic comparison with pure Au NPs, CuS NPs, and other similar metal NPs, are necessary to fully understand the virucidal properties of Au/CuS NPs.
This study only demonstrated the proof-of-concept that Au/CuS NPs exhibited antiviral activity to norovirus VLPs, and much more work is still needed to apply the concept to a practical approach. Nevertheless, the observations here present both challenges and opportunities for further investigations. The challenges would be to elucidate the detailed mechanisms about Au/CuS NPs’ antiviral activity to VLPs, and to investigate its antiviral activity to norovirus surrogates and native human noroviruses. Since using VLPs as the test model would not be possible to study the effect of Au/CuS NPs on the infectivity of noroviruses, further studies on this aspect must be performed using surrogates and/or human noroviruses. On the other hand, the opportunities are such that there is still much room for improvements from the proof-of-concept results in this study if the antiviral activity is confirmed using norovirus surrogates and human noroviruses. There is also opportunity to develop approaches for effective incorporation/utilization of these NPs in practical antiviral agents would be needed. Potential applications of such NPs-incorporated antiviral agents would be disinfectants/sanitizers for decontaminating norovirus contaminated surfaces, especially in hospital or clinical settings, since contaminated surfaces have been reported as a secondary outbreak in many reported norovirus outbreaks because of inadequate disinfection [54, 71]. Rapid and effective antiviral action of NPs-based disinfectants would be useful in preventing the spread of infection by reducing secondary transfer from contaminated surfaces in these settings.
The current lack of rapid, point-of-care inactivation strategies hinders progress in controlling frequent and widespread norovirus outbreaks. Because the most promising virucides directly bind to the viral capsid , inactivation via nanoparticles (NPs) is a more universal alternative to other physical and chemical strategies that exhibit variable efficacy. Using GI.1 VLPs as a model viral system, this study provides proof of concept that Au/CuS core/shell NPs can rapidly inactivate human norovirus. Immunoblotting, dynamic light scattering, and TEM results provided evidence that capsid protein degradation and capsid damage appeared to be the mechanisms associated with inactivation and have a direct dependence on both NPs concentration and treatment time. Nevertheless, this study demonstrated that Au/CuS NPs are promising antivirals, although further studies using HuNoV-rich fecal extracts will be beneficial to confirming the efficacy of Au/CuS NPs against norovirus.
The authors are grateful to Doctor Robert Atmar at the Baylor College of Medicine for generously providing the VLPs and anti-GI.1 VLP antibody for this study. The authors also thank Brittany Mertens for her assistance with DLS optimization and Mrs. Michelle Gignac Plue for her help with TEM imaging at the Shared Materials Instrumentation Facility (SMIF) at Duke. And the authors also acknowledge Clyde Manuel, Matthew Moore, and Drs Blanca Escudero-Abarca, Lee-Ann Jaykus, and Orlin Velev for critical discussions of this study.
Conceived and designed the experiments: JJB LY. Performed the experiments: JJB BA CY LM AA. Analyzed the data: JJB BA LY. Contributed reagents/materials/analysis tools: CY LM WC. Wrote the paper: JJB LY.
- 1. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology. 2006;346(2):312–23. Epub 2005/12/14. pmid:16343580.
- 2. Patel MM, Hall AJ, Vinje J, Parashar UD. Noroviruses: a comprehensive review. J Clin Virol. 2009;44(1):1–8. Epub 2008/12/17. pmid:19084472.
- 3. Hall AJ, Vinje J, Lopman B, Park GW, Yen C, Gregoricus N, et al. Updated norovirus outbreak management and disease prevention guidelines. MMWR. 2011;60(RR03).
- 4. Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, et al. Norwalk virus: how infectious is it? J Med Virol. 2008;80(8):1468–76. Epub 2008/06/14. pmid:18551613.
- 5. Liu P, Chien Y-W, Papafragkou E, Hsiao H-M, Jaykus L-A, Moe C. Persistence of Human Noroviruses on Food Preparation Surfaces and Human Hands. Food Environ Virol. 2009;1(3–4):141–7.
- 6. D'Souza DH, Sair A, Williams K, Papafragkou E, Jean J, Moore C, et al. Persistence of caliciviruses on environmental surfaces and their transfer to food. Int J Food Microbiol. 2006;108(1):84–91. Epub 2006/02/14. pmid:16473426.
- 7. Thornton SA, Sherman SS, Farkas T, Zhong W, Torres P, Jiang X. Gastroenteritis in US Marines during Operation Iraqi Freedom. Clin Infect Dis. 2005;40(4):519–25. Epub 2005/02/16. pmid:15712073.
- 8. Wadl M, Scherer K, Nielsen S, Diedrich S, Ellerbroek L, Frank C, et al. Food-borne norovirus-outbreak at a military base, Germany, 2009. BMC Infect Dis. 2010;10:30. Epub 2010/02/19. pmid:20163705; PubMed Central PMCID: PMC2831023.
- 9. Yap J, Qadir A, Liu I, Loh J, Tan BH, Lee VJ. Outbreak of acute norovirus gastroenteritis in a military facility in Singapore: a public health perspective. Singapore Med J. 2012;53(4):249–54. Epub 2012/04/19. pmid:22511047.
- 10. England PH. Summary of surveillance of norovirus and rotavirus. PHE Monthly National Report [Internet]. 2014; (10 July):[1–8 pp.].
- 11. Kirking HL, Cortes J, Burrer S, Hall AJ, Cohen NJ, Lipman H, et al. Likely transmission of norovirus on an airplane, October 2008. Clin Infect Dis. 2010;50(9):1216–21. Epub 2010/04/01. pmid:20353365.
- 12. Kornylo K, Kim DK, Widdowson MA, Turabelidze G, Averhoff FM. Risk of norovirus transmission during air travel. J Travel Med. 2009;16(5):349–51. Epub 2009/10/03. pmid:19796107.
- 13. D’Souza DH, Moe CL, Jaykus L-A. Foodborne Viral Pathogens. Food Microbiology: Fundamentals and Frontiers, Third Edition: American Society of Microbiology; 2007.
- 14. Liu P, Escudero B, Jaykus LA, Montes J, Goulter RM, Lichtenstein M, et al. Laboratory evidence of norwalk virus contamination on the hands of infected individuals. Appl Environ Microbiol. 2013;79(24):7875–81. Epub 2013/10/15. pmid:24123733; PubMed Central PMCID: PMC3837815.
- 15. Koo HL, DuPont HL. Noroviruses as a potential cause of protracted and lethal disease in immunocompromised patients. Clin Infect Dis. 2009;49(7):1069–71. Epub 2009/08/27. pmid:19705972.
- 16. Green KY. Norovirus infection in immunocompromised hosts. Clin Microbiol Infect. 2014;20(8):717–23. Epub 2014/07/22. pmid:25040790.
- 17. Lou F, Huang P, Neetoo H, Gurtler JB, Niemira BA, Chen H, et al. High-pressure inactivation of human norovirus virus-like particles provides evidence that the capsid of human norovirus is highly pressure resistant. Appl Environ Microbiol. 2012;78(15):5320–7. Epub 2012/05/29. pmid:22635990; PubMed Central PMCID: PMC3416428.
- 18. Feng K, Divers E, Ma Y, Li J. Inactivation of a human norovirus surrogate, human norovirus virus-like particles, and vesicular stomatitis virus by gamma irradiation. Appl Environ Microbiol. 2011;77(10):3507–17. Epub 2011/03/29. pmid:21441330; PubMed Central PMCID: PMC3126457.
- 19. Bae J, Schwab KJ. Evaluation of murine norovirus, feline calicivirus, poliovirus, and MS2 as surrogates for human norovirus in a model of viral persistence in surface water and groundwater. Appl Environ Microbiol. 2008;74(2):477–84. Epub 2007/12/11. pmid:18065626; PubMed Central PMCID: PMC2223264.
- 20. Pumpens P, Grens E. Artificial gense for chimeric virus-like particles. In: Khudyakov YEF, Fields HA, editor. Artificial DNA: Methods and Applications. Boca Raton, FL: CRC Press; 2002. p. 249–327.
- 21. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines. 2010;9(3):299–307. Epub 2010/03/12. pmid:20218858; PubMed Central PMCID: PMC2862602.
- 22. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends in biotechnology. 2005;23(10):523–9. http://dx.doi.org/10.1016/j.tibtech.2005.07.011. pmid:16084615
- 23. Prasad BV, Rothnagel R, Jiang X, Estes MK. Three-dimensional structure of baculovirus-expressed Norwalk virus capsids. J Virol. 1994;68(8):5117–25. Epub 1994/08/01. pmid:8035511; PubMed Central PMCID: PMC236455.
- 24. Hale A, Mattick K, Lewis D, Estes M, Jiang X, Green J, et al. Distinct epidemiological patterns of Norwalk-like virus infection. J Med Virol. 2000;62(1):99–103. Epub 2000/08/10. pmid:10935995.
- 25. Vimont A, Fliss I, Jean J. Efficacy and mechanisms of murine norovirus inhibition by pulsed-light technology. Appl Environ Microbiol. 2015;81(8):2950–7. Epub 2015/02/15. pmid:25681193; PubMed Central PMCID: PMC4375335.
- 26. Wigginton KR, Kohn T. Virus disinfection mechanisms: the role of virus composition, structure, and function. Curr Opin Virol. 2012;2(1):84–9. Epub 2012/03/24. pmid:22440970.
- 27. Girard M, Ngazoa S, Mattison K, Jean J. Attachment of noroviruses to stainless steel and their inactivation, using household disinfectants. J Food Prot. 2010;73(2):400–4. Epub 2010/02/06. pmid:20132692.
- 28. Macinga DR, Sattar SA, Jaykus LA, Arbogast JW. Improved inactivation of nonenveloped enteric viruses and their surrogates by a novel alcohol-based hand sanitizer. Appl Environ Microbiol. 2008;74(16):5047–52. Epub 2008/07/01. pmid:18586970; PubMed Central PMCID: PMC2519287.
- 29. D'Souza DH, Su X, Roach A, Harte F. High-pressure homogenization for the inactivation of human enteric virus surrogates. J Food Prot. 2009;72(11):2418–22. Epub 2009/11/12. pmid:19903411
- 30. Kingsley DH, Vincent EM, Meade GK, Watson CL, Fan X. Inactivation of human norovirus using chemical sanitizers. Int J Food Microbiol. 2014;171:94–9. Epub 2013/12/18. pmid:24334094.
- 31. Su X, Zivanovic S, D'Souza DH. Effect of chitosan on the infectivity of murine norovirus, feline calicivirus, and bacteriophage MS2. J Food Prot. 2009;72(12):2623–8. Epub 2009/12/17. pmid:20003751
- 32. Ganapathy R. In vitro time and temperature dependence effects of three molecular weights (53, 421, and approximately 1150 kilodalton) chitosans against human noroviral surrogates. Knoxville: University of Tennessee; 2013.
- 33. Lee JE, Ko G. Norovirus and MS2 inactivation kinetics of UV-A and UV-B with and without TiO2. Water Res. 2013;47(15):5607–13. Epub 2013/07/23. pmid:23871257.
- 34. Seo K, Lee JE, Lim MY, Ko G. Effect of temperature, pH, and NaCl on the inactivation kinetics of murine norovirus. J Food Prot. 2012;75(3):533–40. Epub 2012/03/14. pmid:22410228.
- 35. Cannon JL, Papafragkou E, Park GW, Osborne J, Jaykus LA, Vinje J. Surrogates for the study of norovirus stability and inactivation in the environment: aA comparison of murine norovirus and feline calicivirus. J Food Prot. 2006;69(11):2761–5. Epub 2006/12/01. pmid:17133824.
- 36. Escudero-Abarca BI, Rawsthorne H, Goulter RM, Suh SH, Jaykus LA. Molecular methods used to estimate thermal inactivation of a prototype human norovirus: More heat resistant than previously believed? Food microbiology. 2014;41(0):91–5. http://dx.doi.org/10.1016/j.fm.2014.01.009.
- 37. Duizer E, Bijkerk P, Rockx B, De Groot A, Twisk F, Koopmans M. Inactivation of caliciviruses. Appl Environ Microbiol. 2004;70(8):4538–43. Epub 2004/08/06. pmid:15294783; PubMed Central PMCID: PMC492434.
- 38. Bertrand I, Schijven JF, Sanchez G, Wyn-Jones P, Ottoson J, Morin T, et al. The impact of temperature on the inactivation of enteric viruses in food and water: a review. J Appl Microbiol. 2012;112(6):1059–74. Epub 2012/03/03. pmid:22380614.
- 39. Bozkurt H, D'Souza DH, Davidson PM. Thermal inactivation of human norovirus surrogates in spinach and measurement of its uncertainty. J Food Prot. 2014;77(2):276–83. Epub 2014/02/05. pmid:24490922.
- 40. Grove SF, Forsyth S, Wan J, Coventry J, Cole M, Stewart CM, et al. Inactivation of hepatitis A virus, poliovirus and a norovirus surrogate by high pressure processing. Innovative Food Science & Emerging Technologies. 2008;9(2):206–10. http://dx.doi.org/10.1016/j.ifset.2007.07.006.
- 41. Li X, Ye M, Neetoo H, Golovan S, Chen H. Pressure inactivation of Tulane virus, a candidate surrogate for human norovirus and its potential application in food industry. Int J Food Microbiol. 2013;162(1):37–42. Epub 2013/01/29. pmid:23353553.
- 42. Huang R, Li X, Huang Y, Chen H. Strategies to enhance high pressure inactivation of murine norovirus in strawberry puree and on strawberries. Int J Food Microbiol. 2014;185:1–6. Epub 2014/06/14. pmid:24927397.
- 43. Cromeans T, Park GW, Costantini V, Lee D, Wang Q, Farkas T, et al. Comprehensive comparison of cultivable norovirus surrogates in response to different inactivation and disinfection treatments. Appl Environ Microbiol. 2014;80(18):5743–51. Epub 2014/07/13. pmid:25015883; PubMed Central PMCID: PMC4178592.
- 44. Ingle A, Gade A, Pierrat S, Sönnichsen C, Rai MK. Mycosynthesis of silver nanoparticles using the fungus Fusarium acuminatum and its activity against some human pathogenic bacteria. Current Nanoscience. 2008;4:141–4.
- 45. Park S, Park HH, Kim SY, Kim SJ, Woo K, Ko G. Antiviral properties of silver nanoparticles on a magnetic hybrid colloid. Appl Environ Microbiol. 2014;80(8):2343–50. Epub 2014/02/04. pmid:24487537; PubMed Central PMCID: PMC3993170.
- 46. Shionoiri N, Sato T, Fujimori Y, Nakayama T, Nemoto M, Matsunaga T, et al. Investigation of the antiviral properties of copper iodide nanoparticles against feline calicivirus. J Biosci Bioeng. 2012;113(5):580–6. Epub 2012/01/10. pmid:22227118.
- 47. Park GW, Cho M, Cates EL, Lee D, Oh BT, Vinje J, et al. Fluorinated TiO(2) as an ambient light-activated virucidal surface coating material for the control of human norovirus. J Photochem Photobiol B. 2014;140:315–20. Epub 2014/09/16. pmid:25222145.
- 48. Ingle AP, Duran N, Rai M. Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: a review. Appl Microbiol Biotechnol. 2014;98(3):1001–9. Epub 2013/12/07. pmid:24305741.
- 49. Addae E, Dong X, McCoy E, Yang C, Chen W, Yang L. Investigation of antimicrobial activity of photothermal therapeutic gold/copper sulfide core/shell nanoparticles to bacterial spores and cells. J Biol Eng. 2014;8:11. Epub 2014/06/26. pmid:24963345; PubMed Central PMCID: PMC4068869.
- 50. Lakshmanan SB, Zou X, Hossu M, Ma L, Yang C, Chen W. Local field enhanced Au/CuS nanocomposites as efficient photothermal transducer agents for cancer treatment. J Biomed Nanotechnol. 2012;8(6):883–90. Epub 2012/10/04. pmid:23029996.
- 51. Broglie JJ, Moore MD, Jaykus L, Yang L. Design and Evaluation of Three Immuno-based Assays for Rapid Detection of Human Norovirus Virus-like Particles. J Anal Bioanal Tech. 2014;5:220.
- 52. Citkowicz A, Petry H, Harkins RN, Ast O, Cashion L, Goldmann C, et al. Characterization of virus-like particle assembly for DNA delivery using asymmetrical flow field-flow fractionation and light scattering. Anal Biochem. 2008;376(2):163–72. Epub 2008/03/18. pmid:18342613.
- 53. Hardy ME, Tanaka TN, Kitamoto N, White LJ, Ball JM, Jiang X, et al. Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies. Virology. 1996;217(1):252–61. Epub 1996/03/01. pmid:8599210.
- 54. Manuel CS, Moore MD, Jaykus LA. Destruction of the Capsid and Genome of GII.4 Human Norovirus Occurs during Exposure to Metal Alloys Containing Copper. Appl Environ Microbiol. 2015;81(15):4940–6. pmid:25979897
- 55. Cuellar JL, Meinhoevel F, Hoehne M, Donath E. Size and mechanical stability of norovirus capsids depend on pH: a nanoindentation study. J Gen Virol. 2010;91(Pt 10):2449–56. Epub 2010/07/02. pmid:20592107.
- 56. Li WR, Xie XB, Shi QS, Zeng HY, Ou-Yang YS, Chen YB. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol. 2010;85(4):1115–22. Epub 2009/08/12. pmid:19669753.
- 57. Kang S, Herzberg M, Rodrigues DF, Elimelech M. Antibacterial effects of carbon nanotubes: size does matter! Langmuir. 2008;24(13):6409–13. Epub 2008/06/03. pmid:18512881.
- 58. Tang YJ, Ashcroft JM, Chen D, Min G, Kim CH, Murkhejee B, et al. Charge-associated effects of fullerene derivatives on microbial structural integrity and central metabolism. Nano Lett. 2007;7(3):754–60. Epub 2007/02/10. pmid:17288489.
- 59. Mashino T, Okuda K, Hirota T, Hirobe M, Nagano T, Mochizuki M. Inhibition of E. coli growth by fullerene derivatives and inhibition mechanism. Bioorg Med Chem Lett. 1999;9(20):2959–62. Epub 1999/11/26. pmid:10571155.
- 60. Jensen AW, Wilson SR, Schuster DI. Biological applications of fullerenes. Bioorg Med Chem. 1996;4(6):767–79. Epub 1996/06/01. pmid:8818226.
- 61. Tsao N, Luh TY, Chou CK, Chang TY, Wu JJ, Liu CC, et al. In vitro action of carboxyfullerene. J Antimicrob Chemother. 2002;49(4):641–9. Epub 2002/03/23. pmid:11909838.
- 62. Manna SK, Sarkar S, Barr J, Wise K, Barrera EV, Jejelowo O, et al. Single-walled carbon nanotube induces oxidative stress and activates nuclear transcription factor-kappaB in human keratinocytes. Nano Lett. 2005;5(9):1676–84. Epub 2005/09/15. pmid:16159204; PubMed Central PMCID: PMC2743875.
- 63. Narayan RJ, Berry C, Brigmon RL. Structural and biological properties of carbon nanotube composite films. Mater Sci Eng B. 2005;8:123–9.
- 64. Chang Y-N, Zhang M, Xia L, Zhang J, Xing G. The Toxic Effects and Mechanisms of CuO and ZnO Nanoparticles. Materials. 2012;5(12):2850–71.
- 65. Gajjar P, Pettee B, Britt DW, Huang W, Johnson WP, Anderson AJ. Antimicrobial activities of commercial nanoparticles against an environmental soil microbe, Pseudomonas putida KT2440. J Biol Eng. 2009;3:9. Epub 2009/06/30. pmid:19558688; PubMed Central PMCID: PMC2714038.
- 66. El-Nahhal IM, Zourab SM, Kodeh F, Selmane M, Genois I, Babonneau F. Nanostructured copper oxide-cotton fibers: synthesis, characterization, and applications. Int Nano Lett. 2012;2:1–5.
- 67. Warnes SL, Keevil CW. Inactivation of norovirus on dry copper alloy surfaces. PloS one. 2013;8(9):e75017. Epub 2013/09/17. pmid:24040380; PubMed Central PMCID: PMC3767632.
- 68. Warnes SL, Summersgill EN, Keevil CW. Inactivation of murine norovirus on a range of copper alloy surfaces is accompanied by loss of capsid integrity. Appl Environ Microbiol. 2015;81(3):1085–91. Epub 2014/12/03. pmid:25452290; PubMed Central PMCID: PMC4292492.
- 69. Warnes SL, Summersgill EN, Keevil CW. Inactivation of Murine Norovirus on a Range of Copper Alloy Surfaces Is Accompanied by Loss of Capsid Integrity. Appl Environ Microbiol. 2015;81(3):1085–91. PMC4292492. pmid:25452290
- 70. Colvin RA, Fontaine CP, Laskowski M, Thomas D. Zn2+ transporters and Zn2+ homeostasis in neurons. Eur J Pharmacol. 2003;479(1–3):171–85. Epub 2003/11/13. pmid:14612148.
- 71. Morter S, Bennet G, Fish J, Richards J, Allen DJ, Nawaz S, et al. Norovirus in the hospital setting: virus introduction and spread within the hospital environment. Journal of Hospital Infection. 77(2):106–12. pmid:21167622